Trials / Unknown
UnknownNCT01426984
A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults
A Double Blind Crossover Study on the Effect of Methylphenidate on Decision-making Ability of Adults With Borderline Personality Disorder (BPD) Compared to Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Healthy Adults
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Shalvata Mental Health Center · Academic / Other
- Sex
- All
- Age
- 21 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The study assesses the effect of Ritalin on working memory,attention,and decision-making measures in adults with BPD and compares it to its effect on healthy adults and adults with BPD (using data form study SHA 01-10), in a double-blind crossover design. The investigators hypothesize that Ritalin will result in better performance in all measures.
Detailed description
Participants will be required to arrive at the cognitive laboratory in "Shalvata" for two visits: the first visit will include obtaining informed consent, screening (as detailed below), and performing a battery of computerized tasks. The second visit will include performing of the same battery of tasks, and payment. In one of the visits, participants will receive a capsule containing Methylphenidate or placebo (MPH; Ritalin) (dosage: 10 mg in case weight\<40 kg; 30 mg in case weight\>90 kg; otherwise 20 mg -( The pills will be 10mg each, and the number of pills will be administered according to the dosage stated; 1-3 pills, according to weight). Prior to performing the tasks, and in the other visit they will receive a capsule containing placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | methylphenidate | a capsule containing 20 mg |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2011-09-01
- Last updated
- 2012-08-23
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01426984. Inclusion in this directory is not an endorsement.